Business
Adia Nutrition Inc. Announces Landmark Autism Spectrum Disorder Clinical Study Now Live on ClinicalTrials.gov
Winter Park, Florida--(Newsfile Corp. - January 5, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), an emerging leader in regenerative medicine through its subsidiary Adia Med, today announced that its patent-pending clinical study targeting Autism Spectrum Disorder (ASD) has gone live on ClinicalTrials.gov, marking a significant advancement in the company's research pipeline.Clinical trial NCT07304440To view an enhanced version of this graphic, please...
About this update from Adia Nutrition, Inc.
[{"type":"text","content":"Winter Park, Florida--(Newsfile Corp. - January 5, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), an emerging leader in regenerative medicine through its subsidiary Adia Med, today announced that its patent-pending clinical study targeting Autism Spectrum Disorder (ASD) has gone live on ClinicalTrials.gov, marking a significant advancement in the company's research pipeline.","length":377,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":550,"height":274,"url":"https://media.zenfs.com/en/newsfile_64/43598e993c49bc98b24647ccb415f0f1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/I9jusnVVIaFKXBalmnncfA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ3ODtjZj13ZWJw/https://media.zenfs.com/en/newsfile_64/43598e993c49bc98b24647ccb415f0f1","width":550,"height":274}},"href":"https://images.newsfilecorp.com/files/10520/279460_adia.jpg","hrefExternal":true},{"type":"text","content":"Clinical trial NCT07304440","length":26,"tagName":"p","attribs":{}},{"type":"text","content":"To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10520/279460_adia.jpg","length":118,"tagName":"p","attribs":{}},{"type":"text","content":"The randomized interventional study, titled "Adia Med of Winter Park LLC Autism Spectrum Disorder Research Study," aims to enroll approximately 100 children aged 3-12 with confirmed ASD. It evaluates the potential benefits of intravenous glutathione combined with umbilical cord blood-derived stem cells and exosomes (AdiaVita) compared to glutathione alone. Primary outcomes focus on changes in Autism Treatment Evaluation Checklist (ATEC) scores, assessing improvements in speech, sociability, sensory awareness, and behavior. The trial includes a 24-month follow-up period, with patient recruitment beginning in January 2026.","length":638,"tagName":"p"},{"type":"text","content":"Following independent IRB approval from BeyondBound in December 2025, the study completed the ClinicalTrials.gov review process and is now publicly accessible. This development positions Adia Nutrition to generate valuable clinical data in the growing field of regenerative therapies for neurodevelopmental conditions.","length":318,"tagName":"p"},{"type":"text","content":""This milestone of going liv...